Argent Advisors’s GSK GSK Stock Holding History

Argent Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.72M	Sell	51,943 -1,367	-3%	-$72.3K	0.68%	35
2026 Q1	$2.94M	Sell	53,310 -1,251	-2%	-$67.8K	0.8%	35
2025 Q4	$2.68M	Sell	54,561 -1,764	-3%	-$82.3K	0.75%	35
2025 Q3	$2.43M	Sell	56,325 -523	-0.9%	-$20.4K	0.72%	39
2025 Q2	$2.18M	Buy	56,848 +1,971	+4%	+$75.3K	0.67%	40
2025 Q1	$2.13M	Buy	54,877 +22,220	+68%	+$813K	0.71%	39
2024 Q4	$1.1M	Buy	32,657 +2,847	+10%	+$102K	0.41%	70
2024 Q3	$1.22M	Buy	29,810 +1,651	+6%	+$67.5K	0.45%	62
2024 Q2	$1.08M	Buy	28,159 +2,529	+10%	+$106K	0.43%	66
2024 Q1	$1.1M	Buy	25,630 +2,041	+9%	+$84.2K	0.43%	59
2023 Q4	$874K	Buy	+23,589	New	+$847K	0.38%	67
2021 Q3	–	Sell	-9,062	Closed	-$451K	–	135
2021 Q2	$451K	Sell	9,062 -48	-0.5%	-$2.31K	0.27%	88
2021 Q1	$406K	Buy	9,110 +72	+0.8%	+$3.27K	0.26%	93
2020 Q4	$416K	Sell	9,038 -300	-3%	-$13.8K	0.25%	98
2020 Q3	$439K	Buy	9,338 +360	+4%	+$18K	0.3%	86
2020 Q2	$457K	Sell	8,978 -1,803	-17%	-$92.5K	0.35%	76
2020 Q1	$511K	Sell	10,781 -887	-8%	-$47.3K	0.51%	55
2019 Q4	$689K	Buy	+11,668	New	+$649K	0.52%	43

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Argent Advisors's GSK Position: Q2 2026 in Review

Argent Advisors reduced its GSK (GSK) stake by 2.6% in Q2 2026, selling an estimated $72.3K and leaving 51,943 shares worth $2.72M. The position accounts for 0.68% of the portfolio, ranked #35.

Argent Advisors first reported a position in GSK in Q4 2019 and has held it in 18 quarters since. The position peaked at $2.94M in Q1 2026. 1,042 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Argent Advisors held 51,943 shares of GSK worth $2.72M as of Q2 2026.
Argent Advisors sold 1,367 GSK shares in Q2 2026, an estimated $72.3K.
GSK made up 0.68% of Argent Advisors's portfolio in Q2 2026, its #35 holding.
Argent Advisors first reported a position in GSK in Q4 2019 and has held it in 18 quarters since.
Argent Advisors's GSK position peaked at $2.94M in Q1 2026.
1,042 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Argent Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.